Last reviewed · How we verify
Ketamine Co-administered with Propofol
Ketamine and propofol co-administered act synergistically as dissociative and GABAergic anesthetics to produce rapid-onset sedation and analgesia with preserved airway reflexes.
Ketamine and propofol co-administered act synergistically as dissociative and GABAergic anesthetics to produce rapid-onset sedation and analgesia with preserved airway reflexes. Used for Procedural sedation and analgesia, Induction and maintenance of general anesthesia.
At a glance
| Generic name | Ketamine Co-administered with Propofol |
|---|---|
| Sponsor | University of Colorado, Denver |
| Drug class | Anesthetic combination (dissociative + GABAergic) |
| Target | NMDA receptor (ketamine); GABA-A receptor (propofol) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Sedation |
| Phase | Phase 3 |
Mechanism of action
Ketamine is an NMDA receptor antagonist that provides dissociative anesthesia and analgesia, while propofol is a GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission. When combined, they produce complementary effects allowing lower doses of each agent, potentially reducing individual drug-related adverse effects while maintaining anesthetic efficacy and hemodynamic stability.
Approved indications
- Procedural sedation and analgesia
- Induction and maintenance of general anesthesia
Common side effects
- Hypotension
- Respiratory depression
- Emergence reactions (ketamine)
- Injection site pain (propofol)
- Dissociation
Key clinical trials
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- Ketamine Versus Co-administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department (PHASE3)
- Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: